[Tumor cachexia--a special entity and therapeutic sequelae].
Cancer cachexia as a syndrome of generalized host tissue wasting results from interactions of tumor, host and tumor-directed treatment. Cancer cachexia may be associated with all terminal cancer stages and is not tumor-specific. Weight loss, functional impairment and deterioration of the quality of life require palliation. A therapeutic algorithm based on therapeutic standards is proposed: appropriate use of parenteral and enteral nutrition, of progesterone analogues and of metoclopramide. Innovative concepts that may enable prophylactic rather than therapeutic interventions are currently under investigation.
Heberer
M
M
Forschungsabteilung des Departments Chirurgie, Kantonsspital, Universität Basel.
D002100:Cachexia / Q000503:physiopathology / Q000628:therapy*; D003131:Combined Modality Therapy; D004734:Energy Metabolism / Q000502:physiology*; D004750:Enteral Nutrition; D006801:Humans; D008787:Metoclopramide / Q000008:administration & dosage; D009369:Neoplasms / Q000503:physiopathology*; D010166:Palliative Care; D010289:Parenteral Nutrition, Total; D045167:Progesterone Congeners / Q000008:administration & dosage; D011788:Quality of Life
D045167:Progesterone Congeners; D008787:Metoclopramide